{"id":"aliskiren-3-125-mini-tablets","safety":{"commonSideEffects":[{"rate":"5%","effect":"Dizziness"},{"rate":"4%","effect":"Headache"},{"rate":"3%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1639","moleculeType":"Small molecule","molecularWeight":"551.77"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting renin, aliskiren reduces the production of angiotensin II, which leads to vasodilation and decreased aldosterone secretion, ultimately lowering blood pressure.","oneSentence":"Aliskiren is a direct renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I, reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:52:18.463Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Aliskiren 3.125 mini-tablets","genericName":"Aliskiren 3.125 mini-tablets","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aliskiren is a direct renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I, reducing blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}